April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
A Retrospective Study on the Effects of Retisert Implant and Ahmed Valve in Patients with Uveitic Glaucoma
Author Affiliations & Notes
  • Katherine Talcott
    Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA
  • Heeyoon Cho
    Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA
    Ophthalmology, Hanyang University College of Medicine, Seoul, Republic of Korea
  • Lucia Sobrin
    Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA
  • Ann-Marie Lobo
    Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA
  • George N Papaliodis
    Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA
  • Angela Turalba
    Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA
  • Lucy Q Shen
    Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA
  • Footnotes
    Commercial Relationships Katherine Talcott, None; Heeyoon Cho, None; Lucia Sobrin, None; Ann-Marie Lobo, None; George Papaliodis, None; Angela Turalba, None; Lucy Shen, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 6144. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Katherine Talcott, Heeyoon Cho, Lucia Sobrin, Ann-Marie Lobo, George N Papaliodis, Angela Turalba, Lucy Q Shen; A Retrospective Study on the Effects of Retisert Implant and Ahmed Valve in Patients with Uveitic Glaucoma. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6144.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Uveitic glaucoma can be managed with an Ahmed valve although there is a high incidence of elevated intraocular pressure (IOP) postoperatively, presumably from inflammation. Fluocinolone acetonide intravitreal implant (Retisert™) can control intraocular inflammation but causes steroid induced ocular hypertension. This study assesses IOP control in uveitic glaucoma patients undergoing Ahmed valve, Retisert implant, or combination of Ahmed/Retisert implantation.

 
Methods
 

A retrospective chart review identified uveitis patients at the Massachusetts Eye and Ear Infirmary who underwent Ahmed valve and/or Retisert implantation from 2002 to 2012. Data related to glaucoma were collected at the preoperative and final visit. IOP control was assessed at postoperative day 1, months 1, 2, 3 and 6, with IOP elevation defined as IOP>21mmHg, use of additional glaucoma drops, or surgery to treat IOP. Kaplan Meier survival curves compared the incidence of IOP elevation between the groups within the first 6 months after surgery.

 
Results
 

31 eyes in 25 patients with uveitic glaucoma were included, with 13 eyes in the Ahmed, 10 in the Retisert and 8 in the Ahmed/Retisert group, and a mean postoperative follow-up time of 2 years (763±393 days). Preoperatively, the 3 groups were similar in mean logmar VA (1.00 ±0.74), but different in IOP (31.8, 15.1, 22.2 mmHg, respectively) and number of glaucoma drops (3.1, 0.2, 2.9, respectively). At the final visit, the 3 groups were similar in mean logmar VA (0.89±0.75) and IOP (15±7 mmHg). In the Ahmed/Retisert group, no glaucoma drops were used compared to 2 drops in the other groups (p=0.004), but 2 eyes (25%) developed tube erosions compared to none in the Ahmed group (p=0.062). Postoperative IOP was significantly better controlled in the Ahmed/Retisert group compared to Ahmed alone (p=0.0055) (Fig. A). The incidence of IOP elevation was slightly higher in the Retisert alone group compared to Ahmed/Retisert but not statistically significant (p=0.40) (Fig. B).

 
Conclusions
 

IOP control in uveitic glaucoma may be better when Ahmed valve surgery is combined with sustained inflammation management, such as with a Retisert implant. However, the higher incidence of tube erosion in the Ahmed/Retisert group should be considered. Additional studies are needed to confirm the role of aggressive inflammation control in the surgical management of uveitic glaucoma.

     
Keywords: 568 intraocular pressure • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 746 uveitis-clinical/animal model  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×